Induced Modification And Degradation Of Intracellular Proteins In Lysosomes: Methylarginine Targeting Chimera (MrTAC)
Tech ID: 34129 / UC Case 2024-9AV-0
Brief Description
A revolutionary drug modality for the selective modification and degradation of intracellular proteins in lysosomes.
Full Description
Methylarginine Targeting Chimera (MrTAC) is a heterobifunctional small molecule designed to selectively induce
arginine methylation, facilitating the targeted degradation of intracellular proteins within lysosomes. This innovative
approach leverages the enzyme protein arginine N-methyltransferase 1 (PRMT1) to chemically modify proteins,
directing them towards lysosomal degradation, a pathway previously underutilized in targeted protein degradation
therapies.
Suggested uses
- Targeted cancer therapies by degrading disease-causing proteins overexpressed in cancer cells.
- Drug development for diseases associated with protein dysregulation and mutation.
- Research tools for studying protein function and methylation effects on cell biology
Advantages
- High selectivity in targeting specific proteins for degradation without affecting global methylation patterns.
- Utilizes the lysosomal degradation pathway, offering an alternative to proteasomal degradation.
- Capable of degrading proteins across various cell lines, timescales, and doses.
- Drives biological loss-of-function phenotypes affecting survival, transcription, and proliferation.
- Overcomes challenges associated with proteasomal targeting, such as ineffective ubiquitination and protein
mutation.
Patent Status
Patent Pending
Related Materials